tbuckley/cabot-search huggingface dataset:
Spatial and temporal variability of intratumoral <sup>18</sup>F-FDG distribution in patients with cancer.
Authors: Aashish D. Bhatt, Xiao-Feng Li, Geetika Bhatt, Goetz H. Kloecker, Vivek R. Sharma, Ali Cahid Civelek
Journal: Journal of Clinical Oncology (2012)

e21149 Background: We previously reported that in mice models, tumor microenvironment is complex and intratumoral 18 F-FDG distribution is heterogeneous. There were apparent spatial and temporal intratumoral 18 F-FDG distribution changes occurring even within 24-48 hour interval in human cancer cell xenografts grown in nude mice. We hypothesized that what was documented in mice models may also be applicable to human patients with cancer. The objective of this study was to investigate the intratumoral spatial and temporal distribution of 18 F-FDG in cancer patients. Methods: Five patients who had repeat PET/CT scans within 1-28 days and with no interval therapy were identified. All patients had fasted overnight and had blood glucose level of less than 200 mg/dl. They were injected with 8.0-14.0mCi of 18 F-FDG intravenously, and whole body PET/CT scans were performed 60-80 minutes later utilizing a Siemens PET/CT scanner. Each patient’s intratumoral FDG activity distributions were mapped and compared to each other utilizing magnified digital images of the tumors. Results: Intratumoral FDG activity is very heterogeneous. Within the same tumor, there is a wide range of high and low FDG uptake variations. Apparent change in intratumoral FDG distribution was found within as short as a 24 hour interval in the same patient. Although the global tumoral FDG activity and liver FDG activity measured as SUVmaximum and SUVaverage were not significantly different from one PET/CT to another, there were significant spatial changes and variations of the tumor FDG activity between the two PET/CT images. Conclusions: Intratumoral 18 F-FDG uptake is very heterogeneous and manifests both temporal and spatial changes within as short as 24 hours even in untreated cancer patients. This should be taken into consideration during FDG PET based therapy decisions, for example in tumor and nodal staging or radiation therapy planning.
REMORE DIGITAL RECRUITMENT AND ENROLLMENT IN A NATIONWIDE TRIAL OF SCREENING FOR UNDIAGNOSED ATRIAL FIBRILLATION USING A SELF-APPLIED ECG RECORDING PATCH SENSOR: LESSONS FROM THE MSTOPS TRIAL
Authors: Steven R. Steinhubl, Katie Baca-Motes, Alison Edwards, Shawn Edmonds, Rajesh Mehta, Jill Waalen, Marissa M. Ballesteros, Lauren Ariniello, John Fastenau, Chureen Carter, Troy Sarich, Elise Felicione
Journal: Journal of the American College of Cardiology (2017)
PREDICTORS OF IMMEDIATE AND VERY LATE EVENTS AFTER PERCUTANEOUS MITRAL VALVULOPLASTY
Authors: Rafael A. Meneguz-Moreno, Jose de Ribamar Costa, Nisia Gomes, Auristela Ramos, Alfredo Ferreira Neto, Dimytri Siqueira, Mercedes Maldonado, Zilda Meneghelo, Cesar Esteves, Sergio Braga, Amanda Sousa, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2017)
INSERTION OF A MINIATURIZED INSERTABLE CARDIAC MONITOR OUTSIDE THE TRADITIONAL HOSPITAL SETTING: RESULTS FROM THE RIO 2 INTERNATIONAL STUDY
Authors: Prashanthan Sanders, Rishi Anand, Robert Kowal, Christopher Piorkowski, M. Rizwan Sohail, Hans Kragten, Angel Moya, Kurt Stromberg, John D. Rogers
Journal: Journal of the American College of Cardiology (2017)
Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
Authors: Xiaoqing He, Liying Wang, Heimo Riedel, Kai Wang, Yong Yang, Cerasela Zoica Dinu, Yon Rojanasakul
Journal: Molecular Cancer (2017)

Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of the disease mechanisms. We have identified mesothelin as a potentially unique therapeutic target that as a specific advantage appears nonessential in most cell types. Mesothelin (MSLN), a plasma membrane differentiation antigen, is expressed at a high level in many human solid tumors, including 70% of lung cancer and nearly all mesotheliomas. However, the role of MSLN in the disease process and underlying mechanisms is largely unknown.ShRNA knockdown and overexpression of MSLN were performed in human cancer cell lines and corresponding normal cells, respectively. Tumorigenic and metastatic effects of MSLN were examined by tumor sphere formation, migration, and invasion assays in vitro, as well as xenograft tumor assay in vivo. EMT and CSCs were detected by qPCR array, immunoblotting and flow cytometry.MSLN plays a key role in controlling epithelial-to-mesenchymal transition (EMT) and stem properties of human lung cancer and mesothelioma cells that control their tumorigenicity and metastatic potential. Firstly, MSLN was found to be highly upregulated in non-small cell lung cancer (NSCLC) patient tissues and in lung carcinoma and mesothelioma cell lines. Secondly, genetic knockdown of MSLN significantly reduced anchorage-independent cell growth, tumor sphere formation, cell adhesion, migration and invasion in vitro, as well as tumor formation and metastasis in vivo. Thirdly, ectopic overexpression of MSLN induced the malignant phenotype of non-cancerous cells, supporting its role as an oncogene. Finally, mechanistic studies revealed that knockdown of MSLN reversed EMT and attenuated stem cell properties, in addition to inhibiting tumor growth and metastasis.These results indicate an essential role of MSLN in controlling EMT and stem cell properties of human lung cancer and mesothelioma cells. Since EMT is an important process in tumor progression and metastasis, and MSLN is nonessential in most normal tissue, our findings on MSLN may provide new insights into the disease mechanisms and may aid in the development of novel targeted therapy for lung cancer and mesothelioma.
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Authors: Luca S. Belli, Christophe Duvoux, Marina Berenguer, Thomas Berg, Audrey Coilly, Isabelle Colle, Stefano Fagiuoli, Saye Khoo, Georges Philippe Pageaux, Massimo Puoti, Didier Samuel, Mario Strazzabosco
Journal: Journal of Hepatology (2017)
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
Authors: Bartosz Chmielowski, Omid Hamid, David R. Minor, Sandra P. D'Angelo, Gregory K. Pennock, Kenneth Grossmann, Paolo Antonio Ascierto, Adil Daud, Reinhard Dummer, F. Stephen Hodi, Céleste Lebbé, Caroline Robert, Jeffrey Alan Sosman, Arvin Yang, Alexandre Lambert, Jeffrey S. Weber
Journal: Journal of Clinical Oncology (2013)

TPS9105^ Background: Despite the recent approval of ipilimumab and vemurafenib for advanced melanoma, there is still a large unmet need for patients (pts) who have progressed on anti-CTLA-4 therapy and a BRAF inhibitor (depending on BRAF status). Programmed death-1 (PD-1) is a co-stimulation inhibitory receptor that negatively regulates T-cell activation and is upregulated in tumor-infiltrating lymphocytes. Upregulation of PD-1 is also associated with advanced disease in melanoma. Nivolumab, an anti-PD-1 receptor blocking monoclonal antibody, demonstrated durable antitumor activity in a phase 1 study in 106 pts with advanced melanoma with objective responses (OR) observed in 31% and stable disease ≥24 weeks in 6% with a manageable safety profile (Topalian SL et al; ESMO 2012 [Abstr 453P]). Here we describe a phase III study designed to compare the clinical benefit of nivolumab to chemotherapy of investigator’s choice in previously treated pts with unresectable or metastatic melanoma. Methods: In this two arm open-label study, approximately 390 pts will be randomized 2:1 to receive either nivolumab 3 mg/kg IV every two weeks (Arm A) or either dacarbazine 1000 mg/m 2 IV or carboplatin AUC6/paclitaxel 175 mg/m 2 IV every 3 weeks (Arm B) until disease progression or treatment discontinuation. Pts included are those with ≤2 regimens for advanced melanoma who have progressed on anti-CTLA-4 therapy as well as a BRAF inhibitor if BRAF V600-mutation positive. Pts without active brain metastases are eligible. All pts require baseline fresh biopsy to determine PD-L1 expression. Pts will be stratified by tumor PD-L1 expression, BRAF status, and prior anti-CTLA-4 best response. Tumor response per RECIST 1.1 will be assessed 9 weeks following randomization and every 6 weeks thereafter for the first year. After the first year, response will be assessed every 12 weeks until disease progression or treatment discontinuation. The co-primary endpoints are overall survival (OS) and OR rate. Secondary endpoints include progression-free survival, correlation of PD-L1 expression with clinical outcome, and health-related quality of life. Clinical trial information: NCT01721746.
RISK OF HOSPITALIZATION OR DEATH DUE TO HEART FAILURE WITH INTENSIVE GLUCOSE-LOWERING THERAPY IN DIABETIC WOMEN: SUBGROUP ANALYSES BY HISTORY OF CARDIOVASCULAR DISEASE IN THE ACCORD TRIAL
Authors: Tejas Patel, Bereket Tesfaldet, Eileen Navarro Almario, Gyorgy Csako, George Sopko, Jerome Fleg, Ruth Kirby, Charu Gandotra, Helena Sviglin, Keith Burkhart, Karim Calis, Jue Chen, Lawton Cooper, Frank Pucino, Neha Amin, Henry Chang, Sean Coady, Patrice Desvigne Nickens, Peter Kaufmann, Eric Leifer, Lijuan Liu, Subha Raman, Yves Rosenberg, Ahmed Hasan
Journal: Journal of the American College of Cardiology (2017)
Impact of brain metastases on health care costs in metastatic breast cancer: A multinational study
Authors: M. D. Walker, K. Lykopoulos, E. McLeod, S. Cottrell, L. Christova
Journal: Journal of Clinical Oncology (2009)

6555 Background: Incidence of brain metastases (BM) are thought to be particularly high among patients with ErbB2+ (HER2+) breast cancer and have been associated with a poor survival prognosis. A previous study identified such patients as a considerable financial burden for health systems in Germany and France when compared to metastatic breast cancer (MBC) without BM. The objective of this study was to extend that analysis to estimate health care costs in Italy, Spain and the UK. Methods: Patient treatment histories, including drugs, specialist visits, procedures, inpatient stays etc, were collected retrospectively from a panel of oncologists for women with MBC across Italy, Spain and the UK, last seen by the responding oncologist during Q3-Q4 2006 or Q3-Q4 2007. To identify ErbB2+ patients they all had to have received/were receiving trastuzumab (TZ) for MBC. Patients were sampled so as to ensure the collection contained a minimum of 50 cases with BM and 200 histories overall (remainder controls). All costs within the observation period (initiation of TZ to date last seen) were calculated from a payer's perspective for patients who had developed BM and those who had not. Linear stepwise regression took into account potential confounding of time related covariates. Results: The study included 268 Italian (146 cases), 215 Spanish (126 cases) and 243 UK patients (103 cases). BM diagnosis was associated with significantly more expensive treatment histories than those patients without. Service costs such as radiotherapy and hospital visits were found to be key drivers for these differences (p&lt;.001). Conclusions: The significantly greater cost associated with treatment of BMs in ErbB2+ MBC patients from Italy, Spain and the UK is consistent with results from identical French and German analyses. Therapies that reduce the incidence of BMs may therefore decrease the overall financial burden of ErbB2+ MBC. [Table: see text] [Table: see text]
Caregiver evaluation of the quality of end-of-life care (CEQUEL) scale: The caregiver’s perception of patient care near death.
Authors: Philip C Higgins, Holly Gwen Prigerson
Journal: Journal of Clinical Oncology (2013)

6573 Background: End-of-life (EOL) measures are limited in capturing caregiver assessment of the quality of EOL care. None include caregiver perception of patient suffering and prolongation of death. We developed and validated the Caregiver Evaluation of Quality of End-of-Life Care (CEQUEL) scale, a more comprehensive measure of caregiver-perceived quality of EOL care. Methods: Data were derived from Coping with Cancer (CwC), a multisite, prospective, longitudinal study of advanced cancer patients and their caregivers (N=275 dyads). Caregivers were assessed before and after patient deaths. CEQUEL’s factor structure was examined; reliability was evaluated using Cronbach’s α, and convergent validity by the strength of associations between CEQUEL scores and key EOL outcomes. Results: Factor analysis revealed four distinct factors: Prolongation of Death, Perceived Suffering, Shared Decision-Making, and Preparation for the Death. Each item loaded strongly on only a single factor. The 13-item CEQUEL and its subscales showed moderate to acceptable Cronbach’s α (range: 0.52-0.78). 53% of caregivers reported patients suffering more than expected. Higher CEQUEL scores were positively associated with therapeutic alliance (r=.13; p≤.05) and hospice enrollment (z=-2.09; p≤.05), and negatively associated with bereaved caregiver regret (r=-.36, p≤.001) and trauma symptoms (z=-2.06; p≤.05). Conclusions: CEQUEL is a brief, valid measure of quality of EOL care from the caregiver’s perspective. It is the first scale to include perceived suffering and prolongation of death. If validated in future work, it may prove a useful quality indicator for the delivery of EOL care and a risk indicator for poor bereavement adjustment.
STENT EDGE STRUT ON NORMAL SEGMENT IS LESS COVERED IN EARLY PHASE AFTER DRUG ELUTING STENT IMPLANTATION
Authors: Ryota Kakizaki, Yoshiyasu Minami, Takehiro Hashikata, Teruyoshi Nemoto, Kazuhiro Fujiyoshi, Sayaka Namba, Takuya Hashimoto, Tomoyoshi Yanagisawa, Kentaro Meguro, Takao Shimohama, Taiki Tojo, Junya Ako
Journal: Journal of the American College of Cardiology (2017)
RIVAROXABAN USERS HAVE SIGNIFICANTLY LESS TREATMENT DISCONTINUATION COMPARED WITH USERS OF OTHER ORAL ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION
Authors: Colleen McHorney, Veronica Ashton, François Laliberté, Guillaume Germain, Willy Wynant, Concetta Crivera, Jeffrey Schein, Patrick Lefebvre, Eric Peterson
Journal: Journal of the American College of Cardiology (2017)
Utilization of oncotype DX in node-negative, ER-positive breast cancer patients
Authors: H. Patel, K. Hook, C. Kaplan, R. Davidson, A. DeMichele, K. R. Fox, S. M. Domchek
Journal: Journal of Clinical Oncology (2007)

11067 Background: The 21 gene RT-PCR assay Oncotype DX (Genomic Health, CA) stratifies patients into low, intermediate and high risk for systemic recurrence. The objective of this study was to examine the patterns of use of Oncotype DX in a single institution. Methods: All patients who had ODX testing requested by the University of Pennsylvania were identified and recurrence scores (RS) obtained. Patient and tumor characteristics, as well as treatment administered, were obtained by chart review for analysis. Results: 100 ODX tests were ordered between 1/1/05–11/30/06. RS results classified 51% of breast cancers as low risk, 38% intermediate risk, and 11% high risk. Characteristics of the tumors of the overall population and by RS group are shown in Table . 99% of patients received hormonal therapy. Of the low risk patients, only one patient was treated with chemotherapy (2%) while 34% of the intermediate risk group and 80% of the high risk group received chemotherapy. Notably, only 4/100 patients with ODX were under age 35 and 17/100 had tumors over 2cm. Conclusions: In this series, ODX use is accelerating. The results of the ODX tests appear to be used clinically as demonstrated by the very low use of chemotherapy in the low risk group. Comparison to the overall population of ER positive, node negative patients seen at this institution is underway. [Table: see text] No significant financial relationships to disclose.
PROGNOSTIC VALUE OF BASELINE N-TERMINAL PROHORMONE TYPE NATRIURETIC PEPTIDE MEASUREMENT IN CHRONIC LUNG DISEASE PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Pavida Pachariyanon, Sorin Pislaru, Mackram Eleid, Gurpreet Sandhu, Kevin Greason, David Joyce, Vuyisile Nkomo
Journal: Journal of the American College of Cardiology (2017)
Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)
Authors: Claudia Paba-Prada, Antonio Palumbo, Ulf-Henrik Mellqvist, Peter M Voorhees, Torben Plesner, Pieter Sonneveld, Catriona Byrne, Johan Harmenberg, Eva Nordstrom, Paul G. Richardson
Journal: Blood (2014)
THE NATURAL HISTORY OF PARAVALVULAR REGURGITATION AFTER TRANSARTERIAL VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: ONE CENTER EXPERIENCE
Authors: Dragos Alexandru, Timothy Park, Florentina Petillo, Simcha Pollack, George Petrossian, Newell Robinson, Dennis Mihalatos, Eddy Barasch
Journal: Journal of the American College of Cardiology (2017)
Pegylated arginase treatment in mesothelioma xenograft models.
Authors: James C. M. Ho, Sze Kwan Lam, kin Pong U, Paul Ning-Man Cheng
Journal: Journal of Clinical Oncology (2016)

e20083 Background: Cancers with deficient argininosuccinate synthetase (ASS) and/or ornithine transcarbamylase (OTC) are biologically vulnerable to arginine depletion. Preliminary clinical data had suggested a therapeutic role of arginine depletion in malignant pleural mesothelioma (MPM). Pegylated arginase (PEG-BCT-100 (rhArg1peg5000)) works as an arginine depletor with ongoing clinical trials. We postulate that BCT-100 can exert anticancer effect on MPM. Methods: The activity of BCT-100 was tested in a panel of mesothelioma cell lines (H28, 211H, H226, H2052 and H2452). Cell viability was measured using crystal violet staining. Protein expression was evaluated by Western Blot. Arginine concentration was detected by ELISA. Nude mice subcutaneous xenograft models(XMs) derived from 211H and H226 cells were used for in vivo study. BCT-100 was administered via intraperitoneal injection in XMs. Results: BCT-100 reduced in vitro cell viability (13-24 mU/ml) across different cell lines and suppressed tumor growth in both XMs. ASS was expressed in H28, H226, H2452 cells as well as 211H and H266 XMs. OTC was undetectable in all cell lines and XMs. BCT-100 (60 mg/kg) significantly suppressed tumor growth (41% of control on day 20 in 211H XM, 44% of control on day 35 in H226 XM), with increased median survival (from 22 to 38 days in 211H XM (p < 0.001) and from 36.5 to 50.5 days in H226 XM (p < 0.01)). BCT-100 decreased serum arginine concentration (100 mm to < 20 mM, p < 0.001). Moreover, intratumoral arginine content was decreased with 20 mg/kg BCT-100 treatment (p < 0.001 compared with control), which was further reduced in 60 mg/kg arm (20 Vs 60 mg/kg, p < 0.01). Apoptosis (PARP cleavage in 211H XM and Bcl-2 downregulation and cleavage of PARP and caspase 3 in H226 XM) and G1 arrest (downregulation of cyclin A2, D3, E1 and CDK4 in 211H and suppression of cyclin A2, E1, H and CDK4 in H226 XM) were evident with BCT-100 treatment. Conclusions: BCT-100 (pegylated arginase) reduced cell viability in vitro, suppressed growth of tumor xenografts and increased median survival in XMs of MPM. The mechanisms were mediated by arginine depletion resulting in apoptosis and G1 arrest.
THE PROGNOSTIC VALUE OF SERIAL STRESS MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC END-STAGE RENAL DISEASE PATIENTS AWAITING KIDNEY TRANSPLANTATION
Authors: Chiedozie Anokwute, Ibtihaj Fughhi, Marwan Wassouf, Michael Kharouta, Tania Campagnoli, Aviral Vij, George Khoudary, Rozi Khan, Meron Teshome, Andrew Appis, Rami Doukky
Journal: Journal of the American College of Cardiology (2017)
CORONARY ARTERY STRUCTURAL REMODELING BY COMPUTED TOMOGRAPHY AND ECHOCARDIOGRAPHIC LEFT VENTRICULAR MASS CHANGES OVER THE NEXT 5 YEARS: THE CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY
Authors: Aristotelis Papayannis, Daniel Duprez, Yaorong Ge, James Terry, Edmond Kabagambe, Donald Lloyd-Jones, Joao Lima, Bharath Ambale-Venkatesh, Satoru Kishi, John Carr, David Jacobs
Journal: Journal of the American College of Cardiology (2017)
PROSPECTIVE EVALUATION OF LOW-DOSE CORONARY CALCIUM SCORING WITH REDUCED TUBE VOLTAGE
Authors: Christoph Gräni, Jan Vontobel, Dominik Benz, Sara Bacanovic, Beatrice Hirt Moch, Michael Messerli, Marvin Grossmann, Cathérine Gebhard, Aju Paul Pazhenkottil, Oliver Gaemperli, Philipp Kaufmann, Ronny Buechel
Journal: Journal of the American College of Cardiology (2017)
A Study of Symptom Burdens Related to Chemotherapy-Induced Anemia in Patients Diagnosed with Breast Cancer, Lung Cancer and Non-Hodgkin Lymphoma
Authors: Chun Chao, Leila Family, Kimberly Cannavale, Andrew Pourmoussa, Lanfang Xu, Mehta Bhakti, Hairong Xu
Journal: Blood (2016)
TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH AN EXTREMELY SMALL ANNULUS
Authors: Fumiaki Yashima, Masanori Yamamoto, Makoto Tanaka, Ryo Yanagisawa, Takahide Arai, Keiichi Fukuda, Yusuke Watanabe, Toru Naganuma, Shinichi Shirai, Motoharu Araki, Norio Tada, Futoshi Yamanaka, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2017)
THE UTILITY OF MINIMAL CORONARY ARTERY CALCIFICATION FOR PREDICTING CAROTID ARTERY DISEASE: RESULTS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Kazuhiro Osawa, Rine Nakanishi, Robyn McClelland, Ralph Sacco, Joseph Polak, Warrick Bishop, Negin Nezarat, Mitsuru Kanisawa, Sina Rahmani, Indre Ceponience, Hong Qi, Matthew Budoff
Journal: Journal of the American College of Cardiology (2017)
COMPUTED TOMOGRAPHY-DERIVED CORRECTED CONTRAST OPACIFICATION DECREASE PREDICTS REDUCED RELATIVE FLOW RESERVE DERIVED FROM PET MYOCARDIAL PERFUSION IMAGING
Authors: Dominik C. Benz, Christoph Gräni, Paola Ferro, Luis Neumeier, Michael Messerli, Oliver Gaemperli, Aju Paul Pazhenkottil, Philipp Kaufmann, Ronny Buechel
Journal: Journal of the American College of Cardiology (2017)